Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Entasis Therapeutics Holdings Inc (ETTX)

Entasis Therapeutics Holdings Inc (ETTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,796
  • Shares Outstanding, K 47,852
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,140 K
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.30
Trade ETTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.83
  • Most Recent Earnings $-0.32 on 04/27/22
  • Latest Earnings Date 08/10/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +3.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.18 +0.46%
on 07/05/22
2.20 -0.45%
on 07/08/22
unch (unch)
since 06/08/22
3-Month
1.75 +25.14%
on 05/18/22
2.20 -0.45%
on 07/08/22
+0.34 (+18.38%)
since 04/08/22
52-Week
1.40 +56.43%
on 02/01/22
3.88 -43.56%
on 09/20/21
-0.27 (-11.16%)
since 07/08/21

Most Recent Stories

More News
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq:...

INVA : 15.24 (-0.33%)
ETTX : 2.19 (-0.45%)
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TMX, HR, MN, MICT, ETTX

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TMX : 37.87 (-0.50%)
HR : 14.15 (+1.51%)
MN : 12.85 (+0.16%)
MICT : 0.9261 (+2.90%)
ETTX : 2.19 (-0.45%)
SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

BHVN : 54.69 (-4.09%)
SWCH : 34.25 (+0.06%)
ETTX : 2.19 (-0.45%)
INVA : 15.24 (-0.33%)
TVTY : 32.50 (+0.06%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates FHLT, TVTY, MN, ETTX

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

FHLT : 10.78 (+1.41%)
TVTY : 32.50 (+0.06%)
MN : 12.85 (+0.16%)
ETTX : 2.19 (-0.45%)
SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

ETTX : 2.19 (-0.45%)
INVA : 15.24 (-0.33%)
TVTY : 32.50 (+0.06%)
MANT : 95.98 (-0.01%)
RTLR : 15.22 (+2.91%)
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company...

ETTX : 2.19 (-0.45%)
Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of Entasis Therapeutics Holdings Inc. (“Entasis”)...

ETTX : 2.19 (-0.45%)
INVA : 15.24 (-0.33%)
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

REGN : 962.49 (-0.39%)
SNY : 48.60 (-1.90%)
ETTX : 2.19 (-0.45%)
INMB : 11.75 (+1.03%)
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.

GSK : 42.87 (-0.28%)
ALKS : 27.07 (-0.66%)
INVA : 15.24 (-0.33%)
ETTX : 2.19 (-0.45%)
ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Entasis Therapeutics Holdings Inc. (NasdaqGM:...

ETTX : 2.19 (-0.45%)
INVA : 15.24 (-0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The company's product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. Entasis Therapeutics Holdings, Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 2.21
2nd Resistance Point 2.20
1st Resistance Point 2.20
Last Price 2.19
1st Support Level 2.19
2nd Support Level 2.18
3rd Support Level 2.18

See More

52-Week High 3.88
Fibonacci 61.8% 2.93
Fibonacci 50% 2.64
Fibonacci 38.2% 2.35
Last Price 2.19
52-Week Low 1.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar